Clinical Evidence: What the Trials Show for Both Treatments
Monjaro vs Wegovy: Understanding the Clinical Evidence
When comparing Monjaro versus Wegovy, it's essential to examine the robust clinical trial data supporting both treatments. In clinical trials, patients taking Wegovy alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks in the landmark STEP 1 trial (Wilding et al., NEJM, 2021). The STEP programme demonstrated sustained results, with STEP 5 showing clinically studied weight loss maintained at two years. Monjaro's SURMOUNT trials revealed impressive outcomes using a different mechanism, though direct head-to-head comparisons aren't available due to different trial designs and populations.
Both Monjaro and Wegovy represent significant advances in prescription weight management, each offering unique benefits for UK patients. Wegovy operates as a GLP-1 receptor agonist, whilst Monjaro functions as a dual GIP and GLP-1 receptor agonist. This mechanistic difference means some patients may respond better to one treatment over the other. The SELECT cardiovascular outcomes trial also demonstrated that Wegovy reduced major cardiovascular events by 20% in eligible patients. Both treatments are available from EverydayMeds, and your prescriber can help determine which approach aligns best with your clinical profile and weight management goals.
Monjaro vs Wegovy: UK Pricing and Value Comparison
Understanding the cost implications when choosing between Monjaro and Wegovy helps UK patients make informed decisions about their weight management investment. Wegovy pricing at EverydayMeds starts from £79.99 for the 0.25mg starter dose (after applying code FIRST40 for new customers), progressing through £94.99 for 0.5mg, £99.99 for 1mg, £139.99 for 1.7mg, and £209.99 for the 2.4mg maintenance dose. Our convenient bundle options include the Intro Duo (0.25mg and 0.5mg pens) for £169.99, whilst the Ultimate Stability Trio provides three months of 2.4mg maintenance supply for £649.99. Returning customers can apply code DOSE25 at checkout for ongoing value.
Both Monjaro and Wegovy require similar dose escalation schedules, making the practical costs comparable over the initial 16-week titration period. EverydayMeds' Take-It-Slow bundles accommodate patients who need extended time at lower doses, such as the Gentle Start Trio (two 0.25mg pens plus one 0.5mg pen) for £269.99. Our GPhC-registered pharmacy (#9012878) ensures competitive pricing without compromising on medication authenticity or cold-chain delivery standards. The 3-minute online clinical assessment process remains identical whether you're prescribed Monjaro or Wegovy, with standard prescriber review taking three working days or express 24-hour options available.
STEP Trial Results: Wegovy's Clinical Evidence Base
The comprehensive STEP clinical programme provides robust evidence for Wegovy's effectiveness in UK weight management contexts. STEP 1 enrolled 1,961 adults without diabetes, demonstrating that patients taking Wegovy alongside reduced-calorie diet and increased physical activity achieved approximately 15% average weight loss compared to 2.4% with placebo at 68 weeks. STEP 3 combined Wegovy with intensive behavioural therapy, resulting in approximately clinically studied weight loss, whilst STEP 2 focused on patients with type 2 diabetes, showing 9.6% average weight reduction.
The durability of Wegovy's effects was confirmed in STEP 5, where patients maintained approximately clinically studied weight loss at the two-year mark when continuing treatment alongside lifestyle modifications. However, the STEP 1 extension study revealed that patients regained approximately two-thirds of lost weight within one year of discontinuing treatment, emphasising that weight management requires long-term commitment. These findings support Wegovy's role as part of a comprehensive approach rather than a standalone solution.
How Wegovy Works: The GLP-1 Mechanism
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics a natural hormone produced in your intestines when you eat. This prescription-only medicine works by binding to GLP-1 receptors in your brain's appetite centres, helping to reduce hunger signals and promote feelings of fullness after smaller meals. Unlike Monjaro's dual-action approach, Wegovy focuses specifically on the GLP-1 pathway, which has been extensively studied in weight management research. The once-weekly injection using Novo Nordisk's FlexTouch pen system provides consistent medication levels throughout the week. Clinical studies suggest that Wegovy may also reduce food cravings and slow gastric emptying, contributing to its weight management effects when used alongside a reduced-calorie diet and increased physical activity.
EverydayMeds Ordering Process: From Assessment to Delivery
Starting your Monjaro vs Wegovy comparison through EverydayMeds begins with our streamlined 3-minute online clinical assessment, designed to evaluate your suitability for prescription weight management treatment. Our qualified prescribers review your medical history, current medications, and weight management goals to determine which treatment may be most appropriate for your circumstances. Standard prescriber review takes three working days, though express 24-hour review is available for urgent requirements. Once approved, your prescription-only medicine is dispensed by our GPhC-registered pharmacy (#9012878) and shipped via next-day delivery using temperature-controlled cold-chain logistics. Our comprehensive service includes ongoing clinical support throughout your weight management journey, ensuring optimal treatment outcomes whether you're prescribed Monjaro or Wegovy.
Storage and Practical Considerations: Monjaro vs Wegovy
Practical storage requirements present one key difference when comparing Monjaro versus Wegovy for UK patients. Wegovy offers superior storage flexibility, remaining stable at room temperature (below 30°C) for up to six weeks once removed from refrigeration, compared to Monjaro's 21-day room temperature limit. Both treatments require refrigeration at 2-8°C before first use, making them suitable for most UK households with standard refrigeration facilities. Wegovy's FlexTouch pen system provides precise dose delivery throughout the mandatory escalation schedule: 0.25mg for weeks 1-4, 0.5mg for weeks 5-8, 1mg for weeks 9-12, 1.7mg for weeks 13-16, and 2.4mg for maintenance dosing from week 17 onwards. The extended room temperature stability makes Wegovy particularly convenient for UK patients who travel frequently or have variable refrigeration access, though both treatments maintain their effectiveness when stored according to manufacturer guidelines.
UK-Specific Considerations for Monjaro vs Wegovy Weight Loss
UK patients comparing Monjaro versus Wegovy benefit from both treatments being fully licensed by the MHRA for weight management in adults with BMI ≥30, or BMI ≥27 with weight-related comorbidities. NICE guideline TA875 recommends Wegovy alongside specialist weight management support, reflecting the NHS's recognition of its clinical value. The UK's regulated healthcare environment ensures that both Monjaro and Wegovy are subject to rigorous safety monitoring, with both treatments carrying the black triangle (▼) symbol indicating additional monitoring of potential side effects.
British patients often appreciate that both treatments integrate well with UK dietary patterns and lifestyle approaches when prescribed alongside reduced-calorie diets and increased physical activity. EverydayMeds' UK-based clinical team understands local healthcare contexts, ensuring that your Monjaro vs Wegovy decision considers factors relevant to British patients. Our service complies fully with UK pharmaceutical regulations, providing the confidence that comes from choosing a legitimate, regulated pathway to prescription weight management rather than unregulated alternatives that may compromise your safety and treatment outcomes.
Making Your Choice: Expert Guidance Available
Deciding between Monjaro and Wegovy ultimately requires individualised clinical assessment, as both prescription-only medicines offer proven weight management benefits through different mechanisms. EverydayMeds' qualified prescribers evaluate your medical history, current health status, treatment preferences, and practical considerations to recommend the most suitable option for your circumstances. Our clinical team, operating under GPhC registration #9012878, provides ongoing support throughout your treatment journey, monitoring progress and adjusting approaches as needed. Whether you choose Monjaro's dual GIP+GLP-1 action or Wegovy's targeted GLP-1 approach, both treatments are available through our secure online service with prices starting from £79.99 and discount codes FIRST40 for new customers or DOSE25 for returning patients, ensuring you receive genuine medication with full clinical support for optimal weight management outcomes.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
